Outlook on Britain’s Life Science Industry

In this exclusive interview, Fintan Walton talks to Richard Barker, Director General of the Association of the British Pharmaceutical Industry (ABPI). Richard describes the role of the ABPI within the UK pharma/biotech industry, and discusses the key messages that the ABPI is currently involved in passing to the Government and patient groups. He outlines the increase in global competition, its effect on the industry within the UK, and the current affordability issues to UK patients in accessing life-saving drugs. Richard stresses the importance of amicable collaborations between drug development, regulatory authorities and government in ensuring the availability of innovative medicines. The interview is concluded with his outlook on the potential of the industry, and the major issues that must be tackled.

Richard Barker

Dr Richard Barker has more than 20 years’ experience in the healthcare industry, and has held a range of senior leadership roles both in the UK and internationally. His career has spanned the pharmaceutical, biotechnology and medical informatics sectors, thus giving him a broad perspective on the issues facing both healthcare systems and the pharmaceutical industry.

Formerly, Dr Barker was Chief Executive of Chiron’s diagnostic division, General Manager of IBM’s worldwide healthcare business and leader of McKinsey’s European healthcare practice.

The ABPI

The Association of the British Pharmaceutical Industry (ABPI) is the trade association for more than 75 companies in the UK who produceprescription medicines. Its member companies research, develop, manufacture and supply more than 80% of the medicines prescribed through the UK’s National Health Service (NHS).

The ABPI also represents companies engaged in the research and/or development of medicines for human use. In addition, its general affiliate membership is for all other organisations with an interest in the pharmaceutical industry.